Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 09:00 ET | Source: Femasys Inc.

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and...
September 25, 2025 09:00 ET | Source: Femasys Inc.

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 08, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 02, 2025 09:00 ET | Source: Femasys Inc.

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

--Existing investors, including Femasys’ largest shareholders, reaffirm confidence in Femasys’ strategy for growth and impact in women’s health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys...
August 25, 2025 23:44 ET | Source: Femasys Inc.

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide,...
August 21, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform

-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth -- ATLANTA, Aug. 21, 2025 (GLOBE...
August 08, 2025 16:05 ET | Source: Femasys Inc.

Femasys Announces Second Quarter Financial Results for 2025

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...
May 30, 2025 08:00 ET | Source: Femasys Inc.

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide,...
February 11, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of...